Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia

dc.contributor.authorJaime Soto
dc.contributor.authorPaula Soto
dc.contributor.authorAndrea Ajata
dc.contributor.authorDaniela Rivero
dc.contributor.authorCarmelo Luque
dc.contributor.authorCarlos Tintaya
dc.contributor.authorJonathan Berman
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:18:15Z
dc.date.available2026-03-22T14:18:15Z
dc.date.issued2018
dc.descriptionCitaciones: 16
dc.description.abstractBolivian cutaneous leishmaniasis due to <i>Leishmania braziliensis</i> was treated with the combination of miltefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm<sup>2</sup> lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination.
dc.identifier.doi10.4269/ajtmh.18-0183
dc.identifier.urihttps://doi.org/10.4269/ajtmh.18-0183
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/45728
dc.language.isoen
dc.publisherAmerican Society of Tropical Medicine and Hygiene
dc.relation.ispartofAmerican Journal of Tropical Medicine and Hygiene
dc.sourceFundación PROINPA
dc.subjectMiltefosine
dc.subjectPentamidine
dc.subjectLeishmaniasis
dc.subjectLeishmania braziliensis
dc.subjectLeishmania
dc.subjectAdverse effect
dc.subjectCutaneous leishmaniasis
dc.subjectMedicine
dc.subjectLesion
dc.subjectDermatology
dc.titleMiltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia
dc.typearticle

Files